Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
18.46
-0.25 (-1.34%)
At close: Mar 28, 2025, 4:00 PM
18.07
-0.39 (-2.11%)
After-hours: Mar 28, 2025, 5:16 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,662,842
Market Cap
34.70M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4 | 0 | - |
Dec 31, 2023 | 4 | 1 | 33.33% |
Dec 31, 2022 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CVKD News
- 15 days ago - Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Business Wire
- 24 days ago - Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - Business Wire
- 7 weeks ago - Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
- 7 weeks ago - Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - Business Wire
- 2 months ago - Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire
- 3 months ago - Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire
- 3 months ago - Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire
- 4 months ago - Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - PRNewsWire